FOLH1 and cancer: Lutetium-177 vipivotide tetraxetan (PluvictoR) (“vipivo”- targeting moiety Lys-Urea-Glu, the “tide” suffix—peptide nature of this moiety and “tetraxetan” is a DOTA derived from)—is a RLT drug first approved by the FDA on 23 March 2022, for the treatment of prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (NIH, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lutetium-lu-177-vipivotide-tetraxetan, accessed on 16 April 2025).